[Problems of metabolic control in type I XXXX @entity1 with @entity177 ].

@entity1 @entity6 @entity2316 @entity177 @entity4854 @entity413
The aetiopathogenesis of the @entity2316 today is still unknown. Uncontested is the contribution of chronic @entity4854 in the pathogenesis of @entity2316 . For this, there are convincing evidences from clinical and experimental experiences including transplantation surgery. The quality of the metabolic adjustment of the diabetics from the first time of @entity6 manifestation is important to prevent the development of @entity2316 . For this, an almost normoglycemic compensation of the @entity413 metabolism is mandatory. More problematically is the management of the @entity6 metabolism during chronic @entity177 . Considerable fluctuations of the blood @entity413 concentration are predominately in the daily profile. The intensive conventional metabolic therapy by multiple insuline injections under self control of the blood @entity413 level are indicated absolutely in those @entity1 . The therapeutic aim is a smoothing of the blood @entity413 fluctuation. With that it is possible--together with the elimination of hemodynamic risk factors--to delay effectively a progradient decline of the glomerulo-filtration rate and to improve the assumption to an invasive therapy.
